Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 9/20 | 0.40 |
| ▸ | PCNA | P12004 | 9/20 | 0.40 |
| ▸ | THRA | P10827 | 7/20 | 0.40 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.40 |
| ▸ | PPARG | P37231 | 3/20 | 0.40 |
| ▸ | RXRA | P19793 | 2/20 | 0.40 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1525944 | 0.79 | THRB (0.63) | THRBPCNATHRALMNAPOLB | |
| SCHEMBL4453017 | 0.78 | THRB (0.46) | THRBPCNATHRALMNAPOLB | |
| SCHEMBL4238471 | 0.77 | PCNA (0.65) | THRBPCNATHRALMNAPOLB | |
| SCHEMBL6041108 | 0.75 | THRB (0.63) | THRBPCNATHRALMNAPOLB | |
| SCHEMBL4607653 | 0.73 | THRB (0.48) | THRBPCNATHRALMNAPOLB | |
| SCHEMBL8396691 | 0.70 | TTR (0.44) | THRBTHRALMNAHIF1APPARG | |
| SCHEMBL6900178 | 0.68 | KDM4E (0.39) | LMNAPOLBHPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL8733106 | 0.68 | THRB (0.39) | THRBPCNATHRALMNAPOLB | |
| SCHEMBL6474464 | 0.66 | GAA (0.51) | THRBPCNATHRALMNAPOLB | |
| SCHEMBL6473141 | 0.64 | FFAR1 (0.58) | THRBPCNATHRALMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6869930-B1 | Acylated insulin | NOVO NORDISK A/S (DK) | 2005-03-22 | — | — | US | claimed |
| US-6011007-A | ZN2+ COMPLEX. | NOVO NORDISK A/S (DK) | 2000-01-04 | — | — | US | claimed |
| US-10195254-B2 | Myristoylated leptin-related peptides and uses thereof | ALBANY MEDICAL COLLEGE (US) | 2019-02-05 | — | — | US | disclosed |
| US-20170312340-A1 | MYRISTOYLATED LEPTIN-RELATED PEPTIDES AND USES THEREOF | ALBANY MEDICAL COLLEGE (US) | 2017-11-02 | — | — | US | disclosed |
| EP-3180021-A2 | MYRISTOYLATED LEPTIN-RELATED PEPTIDES AND USES THEREOF | Albany Medical College (US) | 2017-06-21 | — | — | EP | disclosed |
| WO-2016025459-A2 | MYRISTOYLATED LEPTIN-RELATED PEPTIDES AND USES THEREOF | ALBANY MEDICAL COLLEGE (US) | 2016-02-18 | — | — | WO | disclosed |
| US-20060030518-A1 | Acylated insulin | SCIAPS, INC. | 2006-02-09 | — | — | US | disclosed |
| US-6869930-B1 | Acylated insulin | NOVO NORDISK A/S (DK) | 2005-03-22 | — | — | US | disclosed |
| US-20040110664-A1 | Acylated insulin | HAVELUND SVEND (DK) | 2004-06-10 | — | — | US | disclosed |
| EP-1132404-A2 | Acylated insulin | NOVO NORDISK A/S (DK) | 2001-09-12 | — | — | EP | disclosed |
| EP-0792290-B1 | ACYLATED INSULIN | NOVO NORDISK AS (DK) | 2001-08-29 | — | — | EP | disclosed |
| WO-1995007931-A1 | ACYLATED INSULIN | NOVO NORDISK A/S (DK) | 1995-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030518-A1 | Acylated insulin | INSR, BCAT1, SLC1A5 | THRB 8/4885PCNA 4586/4885THRA 53/4885 |
| US-20040110664-A1 | Acylated insulin | INSR, BCAT1, INSRR | THRB 17/4885PCNA 4609/4885THRA 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.